- Faculty
- Health
- In the News
Ph II Subcutan Amivantamab in Pts w/ Adv or Metastat SolidTumors EGFR-mutated Non-Small Cell Lung Ca
Misako Nagasaka
A Study On:
- Anus
- Bones and Joints
- Brain and Nervous System
- Breast
- Cervix
- Colon
- Corpus Uteri
- Esophagus
- Eye and Orbit
- Ill-Defined Sites
- Kaposi's Sarcoma
- Kidney
- Larynx
- Lip, Oral Cavity and Pharynx
- Liver
- Lung
- Melanoma, Skin
- Mycosis Fungoides
- Other Digestive Organ
- Other Endocrine System
- Other Female Genital
- Other Male Genital
- Other Respiratory and Intrathoracic Organs
- Other Skin
- Other Urinary
- Ovary
- Pancreas
- Prostate
- Rectum
- Small Intestine
- Soft Tissue
- Stomach
- Thyroid
- Unknown Sites
- Urinary Bladder
Status:
- Open
Eligibility
18 Years and older (Adult, Older Adult )
Interested in joining this trial?
Official Title
A Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
Details
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Eligibility
You can join if...
Inclusion
-Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC)
- articipants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
-May have a prior or concurrent second malignancy
-Have adequate organ
-A participant must agree not to donate eggs (ova, oocytes) or freeze for future use
Exclusion
-Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis
-Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort
-Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1.
-Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5)
-Other clinically active liver disease of infectious origin
-Participant has a history of clinically significant cardiovascular disease
-Participant has symptomatic brain metastases
Get in touch with our study team
News & Events
- Faculty
- Health
- In the News
- Faculty
- Health
- In the News